About the company
Gilead Sciences, a leading biopharmaceutical company, has established itself as a pioneer in the development and marketing of innovative therapies to combat life-threatening infectious diseases. The company has built a strong foundation by focusing on finding effective treatments for HIV and hepatitis B and C, which have posed significant global health challenges. With a commitment to addressing unmet medical needs, Gilead Sciences has expanded its portfolio through a series of strategic acquisitions. By acquiring Corus Pharma, a company specializing in pulmonary diseases, Gilead broadened its focus to include respiratory conditions. This move demonstrated the company's dedication to improving the lives of patients suffering from various respiratory ailments. Recognizing the urgent need for advancements in cardiovascular diseases, Gilead proceeded to acquire Myogen and CV Therapeutics. These acquisitions provided the company with access to cutting-edge therapies targeting heart conditions. By integrating these novel treatments into its portfolio, Gilead showcased its intention to fight against a broader range of diseases with unmet medical needs. To further reinforce its commitment to advancing healthcare, Gilead Sciences made strategic acquisitions such as Arresto Biosciences and Calistoga. These acquisitions allowed Gilead to enter the field of oncology, a major area of medical research. By exploring innovative approaches to treat cancer, Gilead demonstrated its dedication to improving outcomes for patients battling this devastating disease. This expansion into the realm of cancer therapeutics marked a significant milestone for the company. In 2011, Gilead Sciences made a game-changing move by acquiring Pharmasset, a biopharmaceutical company focused on developing a groundbreaking treatment for hepatitis C. This acquisition granted Gilead the rights to Sovaldi, a revolutionary drug that showed unprecedented efficacy in treating hepatitis C. Sovaldi's success paved the way for the development of Harvoni, a combination drug that also included Sovaldi. These two drugs have revolutionized the treatment landscape for hepatitis C, offering patients newfound hope and improved outcomes. Not content to rest on its laurels, Gilead Sciences continued to expand its oncology portfolio by acquiring companies like Kite, Forty Seven, and Immunomedics. These acquisitions allowed Gilead to strengthen its presence in the fields of cell therapy and noncell therapy in oncology. With the adoption of innovative approaches and cutting-edge technologies, Gilead showcased its commitment to delivering transformative therapies for cancer patients. Through strategic acquisitions and a steadfast commitment to research and development, Gilead Sciences has emerged as a global leader in the field of infectious diseases, pulmonary and cardiovascular conditions, and oncology. The company's relentless pursuit of innovative therapies has saved countless lives and continues to shape the future of healthcare. With its diverse portfolio and strong pipeline, Gilead Sciences remains dedicated to developing groundbreaking treatments that address some of the most pressing medical challenges of our time.
Website: https://www.gilead.com
Data updated: June 2, 2026
